Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs
Bullboard Posts
User Avatar Image
(0)
•••
Comment by lovetheoilpatchon May 08, 2015 4:45pm
100 Views
Post# 23710115

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Drug-Packed Exosomes v. BTI

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Drug-Packed Exosomes v. BTIone last thought AS I HEAD OUT FOR ROUND TWO ON THE LYNX TODAY.....a lot of people have asked me why I don't sell...inboxes and such.....its simple....we have no flaws with science here...every news we get is very good and encouraging....im just to optimistic as far as my investment goes....I mean no harm to anyone here either...im past that kind of thinking....I don't understand with the potential that lies for a flawless company like ours on the nasdaq and being stakehorsed by goldman or j.p ...or anyone big in the states why we never went that rout.....personally ...if they wanted 25% of the float and could put us up to say 12$ a share...then who cares....ultimately I com on here mostly out of frustration and unrest....but maybe bti has something in the works that coul;d propel my wealth into the safety zone and then some lol....personally I would have felt more comfortable with this company being moved to the nasdaq ...where the American pharma that we seek an alliance with would most likely be....otherwise all I have are opinions like anyone else here...
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities